TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from The United Laboratories International Holdings ( (HK:3933) ) is now available.
The United Laboratories International Holdings Limited announced that its product, Cefoperazone Sodium and Sulbactam Sodium for Injection, has passed the consistency evaluation by the China National Medical Products Administration. This approval enhances the company’s position in the anti-infective market and is expected to add value for shareholders as the company continues its research and development efforts.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in the production of antibiotics and other pharmaceutical products, with a strong emphasis on anti-infective medications.
Average Trading Volume: 13,479,448
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.68B
For an in-depth examination of 3933 stock, go to TipRanks’ Overview page.